Navigation Links
Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011
Date:4/12/2011

NEW YORK, April 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011

http://www.reportlinker.com/p0479812/Bladder-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020---Volume-1-2011.html

Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011

Summary

GlobalData, the industry analysis specialist, has released its new report, "Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011". The report is an essential source of information and analysis on the global bladder cancer therapeutics market. The report provides comprehensive information on bladder cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global bladder cancer therapeutics market. It analyses the treatment usage patterns in the global bladder cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global bladder cancer sector. It quantifies the unmet need in the global bladder cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The Scope of the report includes:

- An overview of bladder cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized global bladder cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.

- Analysis of unmet need in the market and target product profile including opportunity for target product.

- Technology trends analytic framework to assess strength of pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include dual kinase inhibitors, EGFR inhibitors, microtubule inhibitors, DNA synthesis inhibitors.

- Clinical trials mapping of trials for bladder cancer in different regions.

- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.

- Analysis of the current and future market competition in the global Bladder Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Bristol-Myers Squibb, Spectrum Pharmaceuticals, Inc., Bioniche Life Sciences, Inc., Endo Pharmaceuticals, Eli lilly and Company and Sanofi-aventis.

- Analysis of licensing agreements during 2004-2010 in the bladder cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the bladder cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the global bladder cancer therapeutics market.

- Understanding treatment preferences of physicians in disease state and across treatment flow.

- Accessing market sizing, forecasts and quantified growth opportunities in the global bladder cancer therapeutics market till 2020.

- Quantifying patient population in the global bladder cancer market to better design product pricing & launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- performing benchmarking analysis and growth opportunities against currently marketed products

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.

- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.

- Track drug sales in the global bladder cancer therapeutics market from 2001 to 2020

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the global bladder cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 7

1.2 List of Figures 10

2 Bladder Cancer Therapeutics: Introduction 14

2.1 Bladder Cancer Types 14

2.2 Bladder Cancer by Cell Type 14

2.3 Bladder Cancer by Extent of Metastasis 14

2.4 Symptoms 14

2.5 Risk factors 15

2.6 Prognosis 15

2.7 Diagnosis of Bladder Cancer 16

2.7.1 Physical Examination 16

2.7.2 Urological Tests 16

2.7.3 Cystoscopy and TURBT 16

2.7.4 Imaging Tests 17

2.8 Staging of Bladder Cancer 19

2.9 Treatment of Bladder Cancer 21

2.10 Treatment of Bladder Cancer 22

2.10.1 Surgery 22

2.10.2 TURBT with fulguration 22

2.10.3 Cystectomy 22

2.10.4 Radiation Therapy 23

2.10.5 Immunotherapy 23

2.10.6 Chemotherapy 24

2.11 GlobalData Indepth Report Guidance 25

3 Bladder Cancer Therapeutics: Market Characterization 26

3.1 Global 26

3.1.1 Market Size 26

3.1.2 Drivers and Barriers 31

3.1.3 Forecasts 34

3.1.4 Drug Sales 40

3.2 The US 42

3.2.1 Market Size 42

3.2.2 Drivers and Barriers 47

3.2.3 Forecasts 50

3.2.4 Drug Sales 56

3.2.5 Pricing and Reimbursements 58

3.3 The UK 59

3.3.1 Market Size 59

3.3.2 Drivers and Barriers 64

3.3.3 Impact on the Market 66

3.3.4 Forecasts 67

3.3.5 Drug Sales 73

3.3.6 Pricing and Reimbursements 75

3.4 Germany 76

3.4.1 Market Size 76

3.4.2 Drivers and Barriers 81

3.4.3 Impact on the Market 83

3.4.4 Forecasts 84

3.4.5 Drug Sales 90

3.4.6 Pricing and Reimbursements 92

3.5 France 93

3.5.1 Market Size 93

3.5.2 Drivers and Barriers 98

3.5.3 Impact on the Market 100

3.5.4 Forecasts 101

3.5.5 Drug Sales 107

3.5.6 Pricing and Reimbursements 109

3.6 Italy 110

3.6.1 Market Size 110

3.6.2 Drivers and Barriers 115

3.6.3 Impact on the Market 117

3.6.4 Forecasts 118

3.6.5 Drug Sales 124

3.6.6 Pricing and Reimbursements 126

3.7 Spain 127

3.7.1 Market Size 127

3.7.2 Drivers and Barriers 132

3.7.3 Impact on the Market 134

3.7.4 Forecasts 135

3.7.5 Drug Sales 141

3.7.6 Pricing and Reimbursements 143

3.8 Japan 144

3.8.1 Market Size 144

3.8.2 Drivers and Barriers 149

3.8.3 Impact on the Market 151

3.8.4 Forecasts 152

3.8.5 Drug Sales 158

3.8.6 Pricing and Reimbursements 160

3.9 Brazil 161

3.9.1 Market Size 161

3.9.2 Drivers and Barriers 166

3.9.3 Impact on the Market 168

3.9.4 Forecasts 169

3.9.5 Future Impact 174

3.9.6 Drug Sales 175

3.10 India 177

3.10.1 Market Size 177

3.10.2 Drivers and Barriers 182

3.10.3 Impact on the Market 184

3.10.4 Forecasts 185

3.10.5 Future Impact 190

3.10.6 Drug Sales 191

3.11 China 193

3.11.1 Market Size 193

3.11.2 Drivers and Barriers 198

3.11.3 Impact on the Market 200

3.11.4 Forecasts 201

3.11.5 Future Impact 206

3.11.6 Drug Sales 207

3.12 Russia 209

3.12.1 Market Size 209

3.12.2 Drivers and Barriers 214

3.12.3 Impact on the Market 216

3.12.4 Forecasts 217

3.12.5 Future Impact 222

3.12.6 Drug Sales 223

3.13 Key Takeaway 224

4 Bladder Cancer Therapeutics: Opportunity and Unmet Need 225

4.1.1 Neoadjuvant Treatment 227

4.1.2 Metastatic Bladder Cancer Treatment 228

4.2 Key Takeaway 228

5 Bladder Cancer Therapeutics – Competitive Assessment 229

5.1 Overview 229

5.2 Strategic Competitor Assessment 229

5.3 Product Profile for the Major Marketed Products in the Bladder Cancer Therapeutics Market 230

5.3.1 TICE BCG 230

5.3.2 Valstar (Valrubicin) 231

5.3.3 PLATINOL-AQ (cisplatin Injection) 232

5.3.4 MVAC (Methotrexate, Vinblastine, Adriamycin & Cisplatin) 233

5.3.5 Gemcitabine + Cisplatin 233

5.4 Key Takeaway 234

6 Bladder Cancer Therapeutics: Pipeline Assessment 236

6.1 Overview 236

6.2 Strategic Pipeline Assessment 236

6.2.1 Technology Trends Analytic Framework 236

6.3 Bladder Cancer Therapeutics – Promising Drugs Under Clinical Development 238

6.4 Molecule Profile for Promising Drugs under Clinical Development 238

6.4.1 Javlor (Bristol-Myers Squibb and Pierre Fabre Medicament SA) 238

6.4.2 EOquin (Spectrum Pharmaceuticals and Allergan Inc) 240

6.4.3 Urocidin (Bioniche Life Sciences & Endo Pharma) 240

6.4.4 Larotaxel (Sanofi-aventis) 241

6.4.5 OGX-427 (OncoGeneX Inc) 242

6.5 Bladder Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action 243

6.6 Bladder Cancer Pipeline – Pipeline by Clinical Phases of Development 244

6.6.1 Bladder Cancer Therapeutics – Phase III Clinical Pipeline 244

6.6.2 Bladder Cancer Therapeutics – Phase II Clinical Pipeline 245

6.6.3 Bladder Cancer Therapeutics – Phase I Clinical Pipeline 246

6.6.4 Bladder Cancer Therapeutics – Pre-clinical Pipeline 247

6.6.5 Discontinued / Suspended Drug for Bladder Cancer 247

6.7 Key Takeaway 247

7 Bladder Cancer Therapeutics: Clinical Trials Mapping 248

7.1 Clinical Trials 248

7.1.1 Clinical Trials by Status 249

7.1.2 Clinical Trials by Country 250

7.1.3 Clinical Trials by Phase 251

7.1.4 Clinical Trials by Sponsor Type 252

7.1.5 Clinical Trials – Leading Sponsors 253

7.1.6 Clinical Trials – Leading Company Sponsors by Phase 254

7.2 Patient Recruitment 255

8 Bladder Cancer Therapeutics: Implications for Future Market Competition 256

9 Bladder Cancer Therapeutics: Future Market Players 257

9.1 Introduction 257

9.2 Bristol-Myers Squibb Company 257

9.2.1 Business Description 257

9.2.2 Financial Overview 258

9.2.3 SWOT Analysis 258

9.3 Spectrum Pharmaceuticals, Inc. 263

9.3.1 Business Description 263

9.3.2 Financial Overview 264

9.3.3 SWOT Analysis 264

9.4 Bioniche Life Sciences, Inc. 268

9.4.1 Business Description 268

9.4.2 Financial Overview 269

9.4.3 SWOT Analysis 269

9.5 Endo Pharmaceuticals Holdings Inc. 273

9.5.1 Business Description 273

9.5.2 Financial Overview 274

9.5.3 SWOT Analysis 274

9.6 Sanofi-aventis 278

9.6.1 Business Description 278

9.6.2 Financial Overview 280

9.6.3 SWOT Analysis 280

9.7 Eli Lilly and Company 285

9.7.1 Business Description 285

9.7.2 Financial Overview 286

9.7.3 SWOT Analysis 286

10 Bladder Cancer Therapeutics: Licensing and Partnership Deals 292

10.1.1 Partnerships 292

10.1.2 Licensing Agreements 293

10.1.3 Terminated Licensing Agreements 295

10.2 Mergers & Acquisition Analysis 296

10.2.1 Key Highlights 296

10.3 Expert Opinion 298

10.3.1 The US 298

10.3.2 The UK 299

10.3.3 Germany 300

10.3.4 France 301

10.3.5 Italy 301

11 Bladder Cancer Therapeutics: Appendix 302

11.1 Definitions 302

11.2 Acronyms 302

11.3 Research Methodology 303

11.3.1 Coverage 303

11.3.2 Secondary Research 303

11.3.3 Forecasting 304

11.3.4 Primary Research 307

11.3.5 Expert Panel Validation 307

11.4 Contact Us 307

11.5 Disclaimer 307

11.6 Bibliography 308

1.1 List of Tables

Table 1: Bladder Cancer – TNM (Tumor Node Metastasis) Staging, 2010 19

Table 2: Definitions of Stages 20

Table 3: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2001–2010 26

Table 4: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2010 27

Table 5: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2001–2010 28

Table 6: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2010 29

Table 7: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 34

Table 8: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 35

Table 9: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2011–2020 36

Table 10: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020 37

Table 11: Bladder Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2010 40

Table 12: Bladder Cancer Therapeutics Market, Global, Drug Sales ($m), 2011-2020 41

Table 13: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2001–2010 42

Table 14: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2010 43

Table 15: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2001–2010 44

Table 16: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2001–2010 45

Table 17: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 50

Table 18: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 51

Table 19: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2011–2020 52

Table 20: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 53

Table 21: Bladder Cancer Therapeutics Market, The US, Drug Sales ($m), 2001-2010 56

Table 22: Bladder Cancer Therapeutics Market, The US, Drug Sales ($m), 2011-2020 57

Table 23: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2001–2010 59

Table 24: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2001–2010 60

Table 25: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2001–2010 61

Table 26: Bladder Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2001–2010 62

Table 27: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2011-2020 67

Table 28: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011-2020 68

Table 29: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2011-2020 69

Table 30: Bladder Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011-2020 70

Table 31: Bladder Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2010 73

Table 32: Bladder Cancer Therapeutics Market, The UK, Drug Sales ($m), 2011-2020 74

Table 33: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2001–2010 76

Table 34: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001–2010 77

Table 35: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2001–2010 78

Table 36: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2001–2010 79

Table 37: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2011-2020 84

Table 38: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 85

Table 39: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2011-2020 86

Table 40: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011-2020 87

Table 41: Bladder Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2010 90

Table 42: Bladder Cancer Therapeutics Market, Germany, Drug Sales ($m), 2011-2020 91

Table 43: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2001–2010 93

Table 44: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2010 94

Table 45: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2001–2010 95

Table 46: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2010 96

Table 47: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2011-2020 101

Table 48: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 102

Table 49: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2011-2020 103

Table 50: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011-2020 104

Table 51: Bladder Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2010 107

Table 52: Bladder Cancer Therapeutics Market, France, Drug Sales ($m), 2011-2020 108

Table 53: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2001–2010 110

Table 54: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001–2010 111

Table 55: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2001–2010 112

Table 56: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2001–2010 113

Table 57: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2011-2020 118

Table 58: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 119

Table 59: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2011-2020 120

Table 60: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011-2020 121

Table 61: Bladder Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2010 124

Table 62: Bladder Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011-2020 125

Table 63: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2001–2010 127

Table 64: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001–2010 128

Table 65: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2001–2010 129

Table 66: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2001–2010 130

Table 67: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2011-2020 135

Table 68: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 136

Table 69: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2011-2020 137

Table 70: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011-2020 138

Table 71: Bladder Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2010 141

Table 72: Bladder Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011-2020 142

Table 73: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2001–2010 144

Table 74: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2010 145

Table 75: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2001–2010 146

Table 76: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2001–2010 147

Table 77: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2011-2020 152

Table 78: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 153

Table 79: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2011-2020 154

Table 80: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011-2020 155

Table 81: Bladder Cancer Therapeutics Market, Japan, Drug Sales ($m), 2001-2010 158

Table 82: Bladder Cancer Therapeutics Market, Japan, Drug Sales ($m), 2011-2020 159

Table 83: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2010 161

Table 84: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2010 162

Table 85: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2001–2010 163

Table 86: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2010 164

Table 87: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011-2020 169

Table 88: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 170

Table 89: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2011-2020 171

Table 90: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020 172

Table 91: Bladder Cancer Therapeutics Market, Brazil, Drug Sales ($m), 2001-2010 175

Table 92: Bladder Cancer Therapeutics Market, Brazil, Drug Sales ($m), 2011-2020 176

Table 93: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2001–2010 177

Table 94: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2010 178

Table 95: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2001–2010 179

Table 96: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2010 180

Table 97: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2011-2020 185

Table 98: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 186

Table 99: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2011-2020 187

Table 100: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011-2020 188

Table 101: Bladder Cancer Therapeutics Market, India, Drug Sales ($m), 2001-2010 191

Table 102: Bladder Cancer Therapeutics Market, India, Drug Sales ($m), 2011-2020 191

Table 103: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2001–2010 193

Table 104: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2010 194

Table 105: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2001–2010 195

Table 106: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2010 196

Table 107: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2011-2020 201

Table 108: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 202

Table 109: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2011-2020 203

Table 110: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011-2020 204

Table 111: Bladder Cancer Therapeutics Market, China, Drug Sales ($m), 2001-2010 207

Table 112: Bladder Cancer Therapeutics Market, China, Drug Sales ($m), 2011-2020 208

Table 113: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2010 209

Table 114: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2010 210

Table 115: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2001–2010 211

Table 116: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2010 212

Table 117: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2011-2020 217

Table 118: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 218

Table 119: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2011-2020 219

Table 120: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020 220

Table 121: Bladder Cancer Therapeutics Market, Russia, Drug Sales ($m), 2001-2010 223

Table 122: Bladder Cancer Therapeutics Market, Russia, Drug Sales ($m), 2011-2020 224

Table 123: Major Marketed Products Comparison in the Bladder Cancer Therapeutics Market, 2010 235

Table 124: Bladder Cancer Therapeutics – Most Promising Drugs Under Clinical Development, 2010 238

Table 125: Clinical Trial Results for Javlor, April 2009 239

Table 126: Bladder Cancer Therapeutics – Phase III Clinical Pipeline 244

Table 127: Bladder Cancer Therapeutics – Phase II Clinical Pipeline 245

Table 128: Bladder Cancer Therapeutics – Phase I Clinical Pipeline 246

Table 129: Bladder Cancer Therapeutics – Pre-clinical Pipeline 247

Table 130: Bladder Cancer Therapeutics – Discontinued/Suspended Drugs 247

Table 131: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011 248

Table 132: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011 250

Table 133: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011 251

Table 134: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011 252

Table 135: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011 253

Table 136: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011 254

Table 137: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011 255

Table 138: Bladder Cancer, Global, Licensing Agreements, 2009-2010 295

1.2 List of Figures

Figure 1: Bladder Cancer Histopathology 16

Figure 2: Intravenous Pyelogram 17

Figure 3: Bladder Cancer, CT Scan Image 17

Figure 4: Bladder Cancer, MRI Image 18

Figure 5: Treatment Algorithm for Bladder Cancer 21

Figure 6: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2001–2010 26

Figure 7: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2010 27

Figure 8: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2001–2010 28

Figure 9: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2010 29

Figure 10: Bladder Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2009 31

Figure 11: Bladder Cancer Therapeutics Market, Global, the Impact of Historical Events on the Market, 2010 33

Figure 12: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 34

Figure 13: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 35

Figure 14: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2011–2020 36

Figure 15: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020 37

Figure 16: Bladder Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2010–2020 39

Figure 17: Bladder Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2020 40

Figure 18: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2001–2010 42

Figure 19: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2010 43

Figure 20: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2001–2010 44

Figure 21: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2001–2010 45

Figure 22: Bladder Cancer Therapeutics Market, The US, Market Drivers and Restraints, 2010 47

Figure 23: Bladder Cancer Therapeutics Market, The US, The Impact of Historical Events on the Market, 2010 49

Figure 24: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 50

Figure 25: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 51

Figure 26: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2011–2020 52

Figure 27: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 53

Figure 28: Bladder Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2011–2020 55

Figure 29: Bladder Cancer Therapeutics Market, The US, Drug Sales ($m), 2001-2020 56

Figure 30: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2001–2010 59

Figure 31: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2001–2010 60

Figure 32: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2001–2010 61

Figure 33: Bladder Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2001–2010 62

Figure 34: Bladder Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2010 64

Figure 35: Bladder Cancer Therapeutics Market, the UK, the Impact of Historical Events on the Market, 2010 66

Figure 36: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2011-2020 67

Figure 37: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011-2020 68

Figure 38: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2011-2020 69

Figure 39: Bladder Cancer Therapeutics Market, the UK, Treatment Usage Patterns, 2011-2020 70

Figure 40: Bladder Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011–2020 72

Figure 41: Bladder Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020 73

Figure 42: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2001–2010 76

Figure 43: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001–2010 77

Figure 44: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2001–2010 78

Figure 45: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2001–2010 79

Figure 46: Bladder Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2010 81

Figure 47: Bladder Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2010 83

Figure 48: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2011-2020 84

Figure 49: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 85

Figure 50: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2011-2020 86

Figure 51: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011-2020 87

Figure 52: Bladder Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011–2020 89

Figure 53: Bladder Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2020 90

Figure 54: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2001–2010 93

Figure 55: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2010 94

Figure 56: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2001–2010 95

Figure 57: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2010 96

Figure 58: Bladder Cancer Therapeutics Market, France, Market Drivers and Restraints, 2010 98

Figure 59: Bladder Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2010 100

Figure 60: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2011-2020 101

Figure 61: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 102

Figure 62: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2011-2020 103

Figure 63: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011-2020 104

Figure 64: Bladder Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2011–2020 106

Figure 65: Bladder Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2020 107

Figure 66: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2001–2010 110

Figure 67: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001–2010 111

Figure 68: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2001–2010 112

Figure 69: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2001–2010 113

Figure 70: Bladder Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2010 115

Figure 71: Bladder Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2010 117

Figure 72: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2011-2020 118

Figure 73: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 119

Figure 74: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2011-2020 120

Figure 75: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011-2020 121

Figure 76: Bladder Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011–2020 123

Figure 77: Bladder Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2020 124

Figure 78: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2001–2010 127

Figure 79: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001–2010 128

Figure 80: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2001–2010 129

Figure 81: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2001–2010 130

Figure 82: Bladder Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2010 132

Figure 83: Bladder Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2010 134

Figure 84: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2011-2020 135

Figure 85: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 136

Figure 86: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2011-2020 137

Figure 87: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011-2020 138

Figure 88: Bladder Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011–2020 140

Figure 89: Bladder Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2020 141

Figure 90: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2001–2010 144

Figure 91: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2010 145

Figure 92: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2001–2010 146

Figure 93: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2001–2010 147

Figure 94: Bladder Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2010 149

Figure 95: Bladder Cancer Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2010 151

Figure 96: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2011-2020 152

Figure 97: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 153

Figure 98: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2011-2020 154

Figure 99: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011-2020 155

Figure 100: Bladder Cancer Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011–2020 157

Figure 101: Bladder Cancer Therapeutics Market, Japan, Drug Sales ($m), 2001-2020 158

Figure 102: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2010 161

Figure 103: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2010 162

Figure 104: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2001–2010 163

Figure 105: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2010 164

Figure 106: Bladder Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2010 166

Figure 107: Bladder Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2010 168

Figure 108: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011-2020 169

Figure 109: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 170

Figure 110: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2011-2020 171

Figure 111: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020 172

Figure 112: Bladder Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011–2020 174

Figure 113: Bladder Cancer Therapeutics Market, Brazil, Drug Sales ($m), 2001-2020 175

Figure 114: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2001–2010 177

Figure 115: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2010 178

Figure 116: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2001–2010 179

Figure 117: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2010 180

Figure 118: Bladder Cancer Therapeutics Market, India, Market Drivers and Restraints, 2010 182

Figure 119: Bladder Cancer Therapeutics Market, India, The Impact of Historical Events on the Market, 2010 184

Figure 120: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2011-2020 185

Figure 121: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 186

Figure 122: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2011-2020 187

Figure 123: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011-2020 188

Figure 124: Bladder Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 2011–2020 190

Figure 125: Bladder Cancer Therapeutics Market, India, Drug Sales ($m), 2001-2020 191

Figure 126: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2001–2010 193

Figure 127: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2010 194

Figure 128: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2001–2010 195

Figure 129: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2010 196

Figure 130: Bladder Cancer Therapeutics Market, China, Market Drivers and Restraints, 2010 198

Figure 131: Bladder Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2010 200

Figure 132: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2011-2020 201

Figure 133: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 202

Figure 134: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2011-2020 203

Figure 135: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011-2020 204

Figure 136: Bladder Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 2011–2020 206

Figure 137: Bladder Cancer Therapeutics Market, China, Drug Sales ($m), 2001-2020 207

Figure 138: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2010 209

Figure 139: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2010 210

Figure 140: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2001–2010 211

Figure 141: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2010 212

Figure 142: Bladder Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2010 214

Figure 143: Bladder Cancer Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2010 216

Figure 144: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2011-2020 217

Figure 145: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 218

Figure 146: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2011-2020 219

Figure 147: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020 220

Figure 148: Bladder Cancer Therapeutics Market, Russia, Future Market Drivers and Restraints, 2011–2020 222

Figure 149: Bladder Cancer Therapeutics

To order this report:

: Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Continuous Glucose Monitoring (CGM) Systems - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
2. Reportlinker Adds World In Vitro Diagnostics Market
3. Reportlinker Adds Global Market for Medical Devices, 2nd Edition
4. Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries)
5. Reportlinker Adds Asia Pacific Markets for Dental Bone Graft Substitutes and Other Biomaterials 2011
6. Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries)
7. Reportlinker Adds Global: Pharmaceuticals Industry Guide
8. Reportlinker Adds Asian Vaccine Markets
9. Reportlinker Adds Microscopy Market in Latin America
10. Reportlinker Adds Leading Anti-Cancer Drugs: World Market Prospects 2011-2021
11. Reportlinker Adds Transdermal Drug Delivery - Technologies, Markets, and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
Breaking Medicine Technology:
(Date:5/6/2016)... New York, NY (PRWEB) , ... May 06, 2016 , ... ... Pelagos Hotel & Resort on the north end of the island close to the ... from July 17th- August 10th 2016. , “We continue to have an amazing ...
(Date:5/6/2016)... Utah (PRWEB) , ... May 06, 2016 , ... ... Step, an online provider of career-focused education and corporate training, and the National ... are pleased to announce Maritza Aquino as the second full-tuition scholarship recipient of ...
(Date:5/5/2016)... ... May 05, 2016 , ... TransWipe Volume 3 is a ... Drag and drop a TransWipe preset between two video clips to instantly add a ... to colored panels with customizable color and orientation options. TransWipe Volume 3 is a ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. ... cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous federal approval ... vaping products that entered the market since February 15, 2007. That would essentially ...
(Date:5/5/2016)... SAN FRANCISCO (PRWEB) , ... May 05, 2016 ... ... in the Unites States to promise successful results with IVF and with egg ... Designed to deliver the most patient-centric and highest quality fertility care, Spring Fertility ...
Breaking Medicine News(10 mins):